Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Downgrade
Athira Pharma downgraded to Hold from Buy at Jefferies » 08:05
06/23/22
06/23
08:05
06/23/22
08:05
ATHA

Athira Pharma

$2.84 /

-5.61 (-66.39%)

Jefferies analyst Andrew…

Jefferies analyst Andrew Tsai downgraded Athira Pharma to Hold from Buy with a price target of $3, down from $32. The analyst has decreased confidence in the next Phase III study following the mixed results of ATH-1017's Phase II Alzheimer's study, Tsai tells investors in a research note, adding that new questions have emerged. Tsai says upside will be driven by regulatory clarity in 2H, potential Phase III interim data in 2H, and final data in 1H23, but that Athira has become a "show-me" story.

ShowHide Related Items >><<
ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

06/23/22 Stifel
Athira Pharma downgraded to Hold from Buy at Stifel
06/23/22 JMP Securities
Athira Pharma downgraded to Market Perform from Outperform at JMP Securities
06/22/22 Jefferies
Athira Pharma downgraded to Hold from Buy at Jefferies
05/10/22 BTIG
Athira Pharma initiated with a Buy at BTIG
ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

Downgrade
Athira Pharma downgraded to Hold from Buy at Stifel » 07:48
06/23/22
06/23
07:48
06/23/22
07:48
ATHA

Athira Pharma

$2.84 /

-5.61 (-66.39%)

Stifel analyst Paul…

Stifel analyst Paul Matteis downgraded Athira Pharma to Hold from Buy with a price target of $5, down from $36, after the . the ACT-AD study failed to replicate the early P300 signal demonstrated in the prior Phase 1b study. The analyst, who argues that the best course of action at this point would be to unblind LIFT-AD and "robustly analyze the data," is lowering his view on the odds of success for ATH-1017 to 10% from 30% and also decreased his sales estimates "significantly" to reflect a potential scenario where ATH-1017 is only used as a monotherapy.

ShowHide Related Items >><<
ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

06/23/22 JMP Securities
Athira Pharma downgraded to Market Perform from Outperform at JMP Securities
06/22/22 Jefferies
Athira Pharma downgraded to Hold from Buy at Jefferies
05/10/22 BTIG
Athira Pharma initiated with a Buy at BTIG
04/21/22 Berenberg
Athira Pharma initiated with a Buy at Berenberg
ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

Downgrade
Athira Pharma downgraded to Market Perform from Outperform at JMP Securities » 05:57
06/23/22
06/23
05:57
06/23/22
05:57
ATHA

Athira Pharma

$2.84 /

-5.61 (-66.39%)

JMP Securities analyst…

JMP Securities analyst Jason Butler downgraded Athira Pharma to Market Perform from Outperform with no price target after the ACT-AD trial failed to demonstrate benefit of fosgonimeton in the overall population for both the primary and key secondary endpoints. While he views the risk/reward as "highly positively skewed" should the subgroup findings from the the Phase 2 LIFT-AD trial be replicated in the ongoing Phase 3 LIFTAD trial, he believes additional visibility on plans and timing are needed before becoming more constructive on the stock.

ShowHide Related Items >><<
ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

06/22/22 Jefferies
Athira Pharma downgraded to Hold from Buy at Jefferies
05/10/22 BTIG
Athira Pharma initiated with a Buy at BTIG
04/21/22 Berenberg
Athira Pharma initiated with a Buy at Berenberg
01/05/22 Jefferies
Athira could see up to 13 times upside on 'big' Alzheimer's data, says Jefferies
ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

Wednesday
Downgrade
Athira Pharma downgraded to Hold from Buy at Jefferies » 18:52
06/22/22
06/22
18:52
06/22/22
18:52
ATHA

Athira Pharma

$2.84 /

-5.61 (-66.39%)

Jefferies analyst Andrew…

Jefferies analyst Andrew Tsai downgraded Athira Pharma to Hold from Buy with a price target of $3, down from $32.

ShowHide Related Items >><<
ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

05/10/22 BTIG
Athira Pharma initiated with a Buy at BTIG
04/21/22 Berenberg
Athira Pharma initiated with a Buy at Berenberg
01/05/22 Jefferies
Athira could see up to 13 times upside on 'big' Alzheimer's data, says Jefferies
12/15/21 Goldman Sachs
Athira Pharma initiated with a Neutral at Goldman Sachs
ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

ATHA Athira Pharma
$2.84 /

-5.61 (-66.39%)

On The Fly
Fly Intel: Pre-market Movers » 08:58
06/22/22
06/22
08:58
06/22/22
08:58
AMBA

Ambarella

$68.22 /

+0.885 (+1.31%)

, PRTK

Paratek Pharmaceuticals

$1.89 /

+0.085 (+4.72%)

, NEWR

New Relic

$46.07 /

-0.06 (-0.13%)

, KFY

Korn/Ferry

$53.80 /

+1.985 (+3.83%)

, WGO

Winnebago

$45.79 /

+0.5 (+1.10%)

, LZB

La-Z-Boy

$22.72 /

-0.47 (-2.03%)

, ABNB

Airbnb

$102.25 /

+2.72 (+2.73%)

, DOW

Dow Inc.

$54.92 /

+0.155 (+0.28%)

, PHM

PulteGroup

$37.15 /

+0.885 (+2.44%)

, ATHA

Athira Pharma

$8.45 /

-0.14 (-1.63%)

Check out this morning's…

ShowHide Related Items >><<
WGO Winnebago
$45.79 /

+0.5 (+1.10%)

PRTK Paratek Pharmaceuticals
$1.89 /

+0.085 (+4.72%)

PHM PulteGroup
$37.15 /

+0.885 (+2.44%)

NEWR New Relic
$46.07 /

-0.06 (-0.13%)

LZB La-Z-Boy
$22.72 /

-0.47 (-2.03%)

KFY Korn/Ferry
$53.80 /

+1.985 (+3.83%)

DOW Dow Inc.
$54.92 /

+0.155 (+0.28%)

ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

AMBA Ambarella
$68.22 /

+0.885 (+1.31%)

ABNB Airbnb
$102.25 /

+2.72 (+2.73%)

AMBA Ambarella
$68.22 /

+0.885 (+1.31%)

06/02/22 Baird
Ambarella price target lowered to $125 from $200 at Baird
06/01/22 Craig-Hallum
Ambarella price target lowered to $100 from $170 at Craig-Hallum
06/01/22 Needham
Ambarella price target lowered to $120 from $175 at Needham
06/01/22 Morgan Stanley
Ambarella price target lowered to $114 from $122 at Morgan Stanley
PRTK Paratek Pharmaceuticals
$1.89 /

+0.085 (+4.72%)

05/06/22 H.C. Wainwright
Paratek price target lowered to $20 from $22 at H.C. Wainwright
04/11/22 BTIG
Paratek Pharmaceuticals price target lowered to $30 from $34 at BTIG
03/17/22 H.C. Wainwright
Paratek Pharmaceuticals price target lowered to $22 from $27 at H.C. Wainwright
02/10/22 WBB Securities
Paratek Pharmaceuticals upgraded to Strong Buy from Buy at WBB Securities
NEWR New Relic
$46.07 /

-0.06 (-0.13%)

06/08/22
Baird to hold a conference
05/13/22 RBC Capital
New Relic price target lowered to $45 from $90 at RBC Capital
05/13/22 Truist
New Relic price target lowered to $85 from $95 at Truist
KFY Korn/Ferry
$53.80 /

+1.985 (+3.83%)

06/17/22 Truist
Korn/Ferry price target lowered to $75 from $98 at Truist
03/10/22 Baird
Korn/Ferry price target lowered to $90 from $106 at Baird
12/09/21 Baird
Korn/Ferry price target raised to $106 from $98 at Baird
09/09/21 Baird
Korn/Ferry price target raised to $98 from $89 at Baird
WGO Winnebago
$45.79 /

+0.5 (+1.10%)

05/19/22 DA Davidson
Winnebago cut to Neutral at DA Davidson amid retail weakness
05/19/22 DA Davidson
Winnebago downgraded to Neutral from Buy at DA Davidson
05/16/22 BMO Capital
Winnebago price target lowered to $85 from $95 at BMO Capital
05/05/22 MKM Partners
MKM starts recreation vehicles with 'constructive' stance, LCI top pick
LZB La-Z-Boy
$22.72 /

-0.47 (-2.03%)

ABNB Airbnb
$102.25 /

+2.72 (+2.73%)

06/22/22 JMP Securities
Airbnb downgraded to Market Perform from Outperform at JMP Securities
06/21/22 Gordon Haskett
Accommodation data has favorable read through for Booking, says Gordon Haskett
06/09/22 Goldman Sachs
Airbnb price target lowered to $95 from $150 at Goldman Sachs
06/03/22 Truist
Airbnb price target lowered to $160 from $190 at Truist
DOW Dow Inc.
$54.92 /

+0.155 (+0.28%)

06/22/22 Credit Suisse
Credit Suisse downgrades Dow Inc. to Underperform, lowers price target to $49
06/22/22 Credit Suisse
Dow Inc. downgraded to Underperform from Neutral at Credit Suisse
06/17/22 JPMorgan
Dow Inc. price target lowered to $70 from $80 at JPMorgan
06/17/22 Citi
Dow Inc. downgraded to Neutral from Buy at Citi
PHM PulteGroup
$37.15 /

+0.885 (+2.44%)

06/22/22 RBC Capital
RBC downgrades PulteGroup with housing downturn 'setting in'
06/22/22 RBC Capital
PulteGroup downgraded to Sector Perform from Outperform at RBC Capital
06/21/22 Citi
PulteGroup price target lowered to $43 from $55 at Citi
06/16/22 UBS
PulteGroup price target lowered to $55 from $73 at UBS
ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

05/10/22 BTIG
Athira Pharma initiated with a Buy at BTIG
04/21/22 Berenberg
Athira Pharma initiated with a Buy at Berenberg
01/05/22 Jefferies
Athira could see up to 13 times upside on 'big' Alzheimer's data, says Jefferies
12/15/21 Goldman Sachs
Athira Pharma initiated with a Neutral at Goldman Sachs
WGO Winnebago
$45.79 /

+0.5 (+1.10%)

PRTK Paratek Pharmaceuticals
$1.89 /

+0.085 (+4.72%)

PHM PulteGroup
$37.15 /

+0.885 (+2.44%)

NEWR New Relic
$46.07 /

-0.06 (-0.13%)

LZB La-Z-Boy
$22.72 /

-0.47 (-2.03%)

KFY Korn/Ferry
$53.80 /

+1.985 (+3.83%)

DOW Dow Inc.
$54.92 /

+0.155 (+0.28%)

ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

AMBA Ambarella
$68.22 /

+0.885 (+1.31%)

ABNB Airbnb
$102.25 /

+2.72 (+2.73%)

PHM PulteGroup
$37.15 /

+0.885 (+2.44%)

LZB La-Z-Boy
$22.72 /

-0.47 (-2.03%)

ABNB Airbnb
$102.25 /

+2.72 (+2.73%)

WGO Winnebago
$45.79 /

+0.5 (+1.10%)

PRTK Paratek Pharmaceuticals
$1.89 /

+0.085 (+4.72%)

PHM PulteGroup
$37.15 /

+0.885 (+2.44%)

NEWR New Relic
$46.07 /

-0.06 (-0.13%)

LZB La-Z-Boy
$22.72 /

-0.47 (-2.03%)

DOW Dow Inc.
$54.92 /

+0.155 (+0.28%)

ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

AMBA Ambarella
$68.22 /

+0.885 (+1.31%)

ABNB Airbnb
$102.25 /

+2.72 (+2.73%)

PHM PulteGroup
$37.15 /

+0.885 (+2.44%)

NEWR New Relic
$46.07 /

-0.06 (-0.13%)

DOW Dow Inc.
$54.92 /

+0.155 (+0.28%)

ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

AMBA Ambarella
$68.22 /

+0.885 (+1.31%)

ABNB Airbnb
$102.25 /

+2.72 (+2.73%)

Hot Stocks
Athira Pharma falls 70% after Ph2 study of fosgonimeton did not meet endpoint » 08:03
06/22/22
06/22
08:03
06/22/22
08:03
ATHA

Athira Pharma

$8.45 /

-0.14 (-1.63%)

Shares of Athira Pharma…

Shares of Athira Pharma are down 70% at $2.55 in pre-market trading after the company announced that its topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton in patients with mild-to-moderate Alzheimer's disease did not meeet primary endpoint .

ShowHide Related Items >><<
ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

05/10/22 BTIG
Athira Pharma initiated with a Buy at BTIG
04/21/22 Berenberg
Athira Pharma initiated with a Buy at Berenberg
01/05/22 Jefferies
Athira could see up to 13 times upside on 'big' Alzheimer's data, says Jefferies
12/15/21 Goldman Sachs
Athira Pharma initiated with a Neutral at Goldman Sachs
ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

Hot Stocks
Athira Pharma announces results from ACT-AD Phase 2 study of fosgonimeton » 07:02
06/22/22
06/22
07:02
06/22/22
07:02
ATHA

Athira Pharma

$8.45 /

-0.14 (-1.63%)

Athira Pharma announced…

Athira Pharma announced topline results from its exploratory ACT-AD Phase 2 study of fosgonimeton, ATH-1017, in patients with mild-to-moderate Alzheimer's disease. Fosgonimeton is a small molecule designed to enhance the activity of Hepatocyte Growth Factor and its receptor, MET, which are expressed in the central nervous system to promote brain health and function. "Following compelling ERP P300 latency biomarker data from a small Phase 1b trial over eight days in Alzheimer's patients on fosgonimeton monotherapy, this Phase 2 trial provides valuable insights into the nature of this novel intervention over 26 weeks. ACT-AD was designed as a learning study to further investigate the ERP P300 biomarker signal over 6 months, assess safety in a patient population more representative of the real world, by allowing the use of add-on standard-of-care acetylcholinesterase inhibitors, and explore fosgonimeton's effect on psychometric outcomes, including ADAS-Cog11, to inform the ongoing Phase 3 LIFT-AD study. To that end, this study achieved its goal," said Hans Moebius, M.D., Ph.D., Chief Medical Officer of Athira. "These data points are very encouraging as they indicate the expected pharmacological activity of fosgonimeton by parallel improvement on ERP P300 latency and ADAS-Cog11 and show a favorable safety profile over six months. This is the first time monotherapy fosgonimeton has shown an effect on ADAS-Cog11, suggesting a potential cognitive benefit. We will use these insights for a rational optimization of the ongoing LIFT-AD trial. We plan to seek advice from our scientific advisors, investigators, and ultimately regulators on how to expeditiously analyze and potentially adapt the LIFT-AD study," added Dr. Moebius

ShowHide Related Items >><<
ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

05/10/22 BTIG
Athira Pharma initiated with a Buy at BTIG
04/21/22 Berenberg
Athira Pharma initiated with a Buy at Berenberg
01/05/22 Jefferies
Athira could see up to 13 times upside on 'big' Alzheimer's data, says Jefferies
12/15/21 Goldman Sachs
Athira Pharma initiated with a Neutral at Goldman Sachs
ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

ATHA Athira Pharma
$8.45 /

-0.14 (-1.63%)

Over a week ago
Hot Stocks
Athira Pharma announces formation of Scientific Advisory Board » 07:17
06/07/22
06/07
07:17
06/07/22
07:17
ATHA

Athira Pharma

$8.97 /

-0.175 (-1.91%)

Athira Pharma announced…

Athira Pharma announced the formation of a Scientific Advisory Board comprised of renowned leaders in neurology and neurodegenerative disease research - Drs. John Olichney, Anton Porsteinsson, Marwan Sabbagh, Lon Schneider, Pierre Tairot and Paul Winner. The SAB, chaired by Athira Chief Medical Officer, Dr. Hans Moebius, will offer expert scientific and clinical perspectives to guide the ongoing development of Athira's pipeline of novel, small molecule compounds. Athira's SAB members are: John Olichney, M.D., Professor of Neurology at the University of California, Davis, is an internationally recognized Alzheimer's disease and dementia researcher with expertise in electrophysiology. He directs the Cognitive Electrophysiology and Neuroimaging Lab at the Center for Mind and Brain and the Clinical Trials Unit of the UC Davis ADRC. Anton Porsteinsson, M.D., The William B. and Sheila Konar Professor of Psychiatry, Neurology, Neuroscience, and Medicine and the Director of the University of Rochester Alzheimer's Disease Care, Research and Education Program in Rochester, N.Y., is a renowned investigator for Alzheimer's disease prevention and treatment clinical trials. Marwan Sabbagh, M.D., Professor of Neurology in the Alzheimer's and Memory Disorders Program at Barrow Neurological Institute in Phoenix, Arizona is an established investigator for Alzheimer's disease clinical trials and is currently the editor-in-chief of Neurology and Therapy. Lon Schneider, M.D., Professor of Psychiatry, Neurology, and Gerontology at the Keck School of Medicine of University of Southern California, and the Della Martin Chair in Psychiatry and Neuroscience. Pierre Tariot, M.D., Director of the Banner Alzheimer's Institute in Phoenix, Arizona and Research Professor of Psychiatry at the University of Arizona College of Medicine, is an experienced clinician, researcher, and leader with a special emphasis on design and implementation of clinical trials. Paul Winner, D.O., FAAN, Senior Director of Premiere Research Institute, Director of Palm Beach Memory Disorder Center, Clinical Professor of Neurology Nova Southeastern University Fort Lauderdale, Florida.

ShowHide Related Items >><<
ATHA Athira Pharma
$8.97 /

-0.175 (-1.91%)

ATHA Athira Pharma
$8.97 /

-0.175 (-1.91%)

05/10/22 BTIG
Athira Pharma initiated with a Buy at BTIG
04/21/22 Berenberg
Athira Pharma initiated with a Buy at Berenberg
01/05/22 Jefferies
Athira could see up to 13 times upside on 'big' Alzheimer's data, says Jefferies
12/15/21 Goldman Sachs
Athira Pharma initiated with a Neutral at Goldman Sachs
ATHA Athira Pharma
$8.97 /

-0.175 (-1.91%)

ATHA Athira Pharma
$8.97 /

-0.175 (-1.91%)

ATHA Athira Pharma
$8.97 /

-0.175 (-1.91%)

Over a month ago
Hot Stocks
Athira Pharma continues to urge shareholders to vote for its director nominees » 16:50
05/16/22
05/16
16:50
05/16/22
16:50
ATHA

Athira Pharma

$8.66 /

+0.39 (+4.72%)

Athira Pharma issued the…

Athira Pharma issued the following statement in response to Richard A. Kayne's suspension of his proxy contest: "We appreciate the strong support of our shareholders throughout this process and their recognition of the incredible talent and commitment of the people across Athira. We continue to urge shareholders to vote "FOR" Athira's three director nominees on the WHITE proxy card. The Athira board is highly qualified and actively engaged in the development and execution of Athira's strategy. It has been purpose-built for this phase in the company's evolution. We have the right strategy, as well as the right leadership team and board of directors, to drive Athira's success. As we enter a pivotal chapter, with topline results from the Phase 2 ACT-AD study expected by the end of the second quarter of 2022 and multiple other upcoming clinical milestones, the company will remain focused on doing what is right for Athira, our shareholders, and our patients and their caregivers. We look forward to an ongoing dialogue with our shareholders as we execute our strategy. Athira's board urges shareholders to vote today "FOR" Athira's three director nominees - Joseph Edelman, John M. Fluke, Jr. and Grant Pickering - on the WHITE proxy card."

ShowHide Related Items >><<
ATHA Athira Pharma
$8.66 /

+0.39 (+4.72%)

ATHA Athira Pharma
$8.66 /

+0.39 (+4.72%)

05/10/22 BTIG
Athira Pharma initiated with a Buy at BTIG
04/21/22 Berenberg
Athira Pharma initiated with a Buy at Berenberg
01/05/22 Jefferies
Athira could see up to 13 times upside on 'big' Alzheimer's data, says Jefferies
12/15/21 Goldman Sachs
Athira Pharma initiated with a Neutral at Goldman Sachs
ATHA Athira Pharma
$8.66 /

+0.39 (+4.72%)

ATHA Athira Pharma
$8.66 /

+0.39 (+4.72%)

ATHA Athira Pharma
$8.66 /

+0.39 (+4.72%)

Hot Stocks
Athira Pharma presents preclinical data on ATH-1018, ATH-1019 » 07:28
05/16/22
05/16
07:28
05/16/22
07:28
ATHA

Athira Pharma

$8.27 /

+0.3 (+3.76%)

Athira Pharma announced…

Athira Pharma announced the presentation of preclinical data on two small molecule positive modulators of the HGF/MET signaling pathway, ATH-1018 and ATH-1019, at the 2022 Peripheral Nerve Society Annual Meeting. The research highlights the effect of ATH-1018 and ATH-1019 on neuropathic pain-related behaviors in a preclinical model of streptozotocin-induced diabetic neuropathy. Data demonstrate that measures of pain-related behaviors were significantly improved on testing days across all dose levels for each molecule. Pain-related behaviors were also significantly reduced prior to dosing on day 25 when ATH-1018 or ATH-1019 had been cleared from plasma, suggestive of potentially persistent pain-modifying effects. "Previous work has identified the HGF/MET pathway as a potential therapeutic target for peripheral neuropathies, including diabetic neuropathy, which features components of nerve damage and inflammation. Our preclinical data demonstrates the potential of ATH-1018 and ATH-1019 as therapeutic candidates for painful diabetic neuropathy," said Kevin Church, Ph.D., Executive Vice President, Research of Athira. "We look forward to the continued evaluation of these candidates to further support our pipeline expansion."

ShowHide Related Items >><<
ATHA Athira Pharma
$8.27 /

+0.3 (+3.76%)

ATHA Athira Pharma
$8.27 /

+0.3 (+3.76%)

05/10/22 BTIG
Athira Pharma initiated with a Buy at BTIG
04/21/22 Berenberg
Athira Pharma initiated with a Buy at Berenberg
01/05/22 Jefferies
Athira could see up to 13 times upside on 'big' Alzheimer's data, says Jefferies
12/15/21 Goldman Sachs
Athira Pharma initiated with a Neutral at Goldman Sachs
ATHA Athira Pharma
$8.27 /

+0.3 (+3.76%)

ATHA Athira Pharma
$8.27 /

+0.3 (+3.76%)

ATHA Athira Pharma
$8.27 /

+0.3 (+3.76%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.